

Xue-Ding Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4110213/publications.pdf>

Version: 2024-02-01

48
papers

664
citations

516710

16
h-index

610901

24
g-index

49
all docs

49
docs citations

49
times ranked

1086
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 1857-1864.	6.1	1
2	Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes. <i>Clinical and Translational Science</i> , 2022, 15, 680-690.	3.1	3
3	Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2022, 13, 788824.	3.5	1
4	FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3639-3649.	12.0	4
5	Novel Clinical Biomarkers for Drug-Induced Liver Injury. <i>Drug Metabolism and Disposition</i> , 2022, 50, 671-684.	3.3	5
6	LC-MS/MS quantification of levetiracetam, lamotrigine and 10-hydroxycarbazepine in TDM of epileptic patients. <i>Biomedical Chromatography</i> , 2022, 36, e5393.	1.7	4
7	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. <i>Translational Oncology</i> , 2021, 14, 100951.	3.7	9
8	Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 641-647.	6.1	4
9	Xanthine oxidase activity in thiopurine curative Chinese inflammatory bowel disease patients. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00764.	2.4	2
10	STAT6 polymorphism was correlated with gefitinib-induced diarrhea in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21046-e21046.	1.6	0
11	An integrative scoring system for survival prediction following gefitinib therapy in non-small cell lung cancer: From a long-term real-world study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21041-e21041.	1.6	0
12	Randomised clinical trial: dose optimising strategy by <i>NUDT15</i> genotyping reduces leucopenia during thiopurine treatment of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1124-1133.	3.7	15
13	Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 725-737.	2.5	9
14	Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease. <i>Gastroenterology Report</i> , 2021, 9, 427-434.	1.3	0
15	Association of polymorphisms in C1orf106, IL1RN, and IL10 with post-induction infliximab trough level in Crohn's disease patients. <i>Gastroenterology Report</i> , 2020, 8, 367-373.	1.3	8
16	Polymorphisms of NF- κ B pathway genes influence adverse drug reactions of gefitinib in NSCLC patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 285-293.	2.0	6
17	UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis. <i>Journal of Proteome Research</i> , 2020, 19, 600-609.	3.7	39
18	Correlation of gefitinib and its metabolites with gefitinib induced rash in patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e21712-e21712.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 364-371.	2.8	20
20	Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid monotherapy. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 165-171.	2.2	12
21	The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. <i>Annals of Translational Medicine</i> , 2019, 7, 806-806.	1.7	11
22	Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 5850-5861.	3.3	5
23	Relationship among ETV1 genetic polymorphisms, PFS, and microRNA in gastrointestinal stromal tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22513-e22513.	1.6	0
24	Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?. <i>Cancer Medicine</i> , 2018, 7, 317-324.	2.8	11
25	A rapid and simple HPLC-MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 448-456.	2.8	10
26	A novel correlation between KIT promoter DNA methylation and prognostic of gastrointestinal stromal tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23514-e23514.	1.6	0
27	A rapid and sensitive UHPLC-MS/MS method for quantification of 83b1 in plasma and its application to bioavailability study in rats. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 71-76.	2.8	1
28	Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. <i>Biomedical Chromatography</i> , 2017, 31, e4022.	1.7	13
29	Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1592-1599.	1.9	48
30	Wuzhi Tablet (<i>Schisandra sphenanthera</i> Extract) Is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who Are CYP3A5 Expressers: a Two-Phase Prospective Study. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1114-1119.	3.3	31
31	Next generation sequencing (NGS) in wild type GISTs.. <i>Journal of Clinical Oncology</i> , 2017, 35, e22507-e22507.	1.6	0
32	Genetic markers in <i>CYP2C19</i> and <i>CYP2B6</i> for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 327-340.	2.4	26
33	Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14095-e14095.	1.6	0
34	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. <i>Scientific Reports</i> , 2015, 5, 12675.	3.3	17
35	Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 535-543.	6.1	20
36	Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy. <i>Drug Metabolism and Disposition</i> , 2015, 43, 455-458.	3.3	5

#	ARTICLE	IF	CITATIONS
37	Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 644-650.	6.1	24
38	Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv021-pyv021.	2.1	23
39	Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 855-862.	6.1	4
40	Polymorphisms of ABCG2, ABCB1 and HNF4 β are associated with Lamotrigine trough concentrations in epilepsy patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2015, 30, 282-287.	2.2	38
41	Interactive effects of <i>CYP3A4</i> , <i>CYP3A5</i> , <i>MDR1</i> and <i>NR112</i> polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 1355-1365.	1.3	39
42	Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 110-117.	2.0	27
43	Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 63-73.	1.9	32
44	Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort β -induced activity of cytochrome P450 3A4 enzyme. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 255-261.	2.4	41
45	Single Nucleotide Polymorphisms of the Pregnane X Receptor Gene in Han Chinese and a Comparison with Other Ethnic Populations. <i>Pharmacology</i> , 2008, 81, 350-354.	2.2	12
46	A Pharmacogenetic Study of Pregnane X Receptor (NR112) in Han Chinese. <i>Current Drug Metabolism</i> , 2007, 8, 778-786.	1.2	20
47	Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 44, 224-230.	2.8	10
48	Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography β -tandem mass spectrometry: Application to a clinical herb β -drug interaction study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 852, 534-544.	2.3	52